```html

Zollinger‑Ellison Syndrome Flushing

What is Zollinger‑Ellison syndrome flushing?

Zollinger‑Ellison syndrome (ZES) is a rare neuroendocrine tumor (NET) that usually originates in the pancreas or duodenum and secretes large amounts of gastric acid‑producing hormone gastrin. The excess acid leads to peptic ulcers, abdominal pain, and chronic diarrhea. In a minority of patients, the tumor also releases vasoactive substances (such as histamine, serotonin, or prostaglandins) that cause episodes of facial and upper‑body flushing.

Flushing in ZES is typically described as a sudden, vivid reddening of the skin that may spread from the face and neck to the chest and upper arms. It can be accompanied by a warm or “hot‑flashing” sensation, sweating, and, occasionally, a rapid heartbeat. While flushing itself is not life‑threatening, it signals that the tumor is active and may be secreting other hormones that require prompt medical attention.

Common Causes

Flushing is a symptom that overlaps many disorders. When a patient with ZES experiences flushing, consider both the primary disease and other co‑existing conditions that can intensify or mimic the episode.

• Zollinger‑Ellison syndrome (gastrin‑producing NET) – primary cause of flushing in this context.
• Carcinoid syndrome – another NET that releases serotonin and causes flushing, wheezing, and diarrhea.
• Pheochromocytoma – adrenal medulla tumor that secretes catecholamines, leading to sudden flushing, hypertension, and palpitations.
• Medullary thyroid carcinoma – can produce calcitonin and other vasoactive peptides causing flushing.
• Medication‑induced flushing – vasodilators, niacin, calcium channel blockers, or chemotherapy agents.
• Alcohol intake – especially in individuals with a compromised liver or gastric mucosa.
• Food triggers – hot, spicy foods, caffeine, or foods high in tyramine can provoke flushing in a hyper‑gastrinemic patient.
• Infections – viral (e.g., Epstein‑Barr), bacterial sepsis, or severe COVID‑19 can cause systemic flushing.
• Hormonal changes – menopause, thyroid storm, or adrenal crisis.
• Psychological stress or panic attacks – activation of the sympathetic nervous system can lead to a facial flush.

Associated Symptoms

Flushing in ZES rarely occurs in isolation. The most frequent accompanying features include:

• Severe or burning epigastric pain (often relieved by food initially, then worsened later)
• Recurrent duodenal or gastric ulcers that fail to heal
• Chronic watery diarrhea (up to 5–10 L/day in advanced disease)
• Weight loss or unexplained malnutrition
• Abdominal bloating and flatulence
• Fatigue and weakness from electrolyte disturbances (e.g., hypokalemia)
• Steatorrhea (fatty stools) if pancreatic enzymes are impaired
• Palpitations or tachycardia during flushing episodes
• Skin itching or a “prickly” sensation after the flush subsides (often seen in carcinoid overlap)

When to See a Doctor

Because flushing can be a sign of active hormone‑secreting tumor tissue, early medical evaluation is essential. Contact a health professional promptly if you notice any of the following:

• Flushing that lasts longer than 5–10 minutes or recurs several times a day.
• Severe abdominal pain that does not improve with over‑the‑counter antacids.
• Persistent, voluminous diarrhea (>3 L/day) or sudden dehydration.
• Unexplained weight loss (>5 % of body weight over 3 months).
• Blood in vomit or stool, suggesting ulcer bleeding.
• New‑onset hypertension, rapid heart rate, or dizziness during a flush.
• Any neurological changes (confusion, fainting) during an episode.

Diagnosis

Diagnosing ZES‑related flushing involves confirming the underlying gastrinoma and evaluating the flushing itself. The work‑up is typically performed in a gastroenterology or endocrine oncology clinic.

1. Laboratory Tests

• Fasting serum gastrin level – a value > 1,000 pg/mL strongly suggests ZES (normal < 100 pg/mL). NIH
• Secretin stimulation test – paradoxical rise in gastrin after secretin administration confirms a gastrinoma.
• Chromogranin A – a general NET marker; elevated in > 70 % of ZES patients.
• 24‑hour urinary 5‑HIAA – screens for carcinoid overlap if flushing is prominent.
• Electrolytes, renal function, and liver panel to assess complications from diarrhea or medication.

2. Imaging Studies

• Endoscopic ultrasound (EUS) – high‑resolution view of the pancreas and duodenum, can guide fine‑needle aspiration.
• Somatostatin receptor scintigraphy (Octreoscan) or Ga‑68 DOTATATE PET/CT – detects NETs that express somatostatin receptors, helping locate primary tumor and metastases.
• CT or MRI abdomen – assesses tumor size, local invasion, and liver metastases.
• Upper endoscopy (EGD) – visualizes ulcers and may obtain biopsies to rule out H. pylori.

3. Histopathology

If a lesion is reachable, a biopsy is taken. Pathology will show neuroendocrine granules staining positive for gastrin, chromogranin A, and synaptophysin.

Treatment Options

Management targets two goals: (1) control of acid hypersecretion and flushing, and (2) eradication or control of the tumor.

Medical Therapies

• Proton‑pump inhibitors (PPIs) – high‑dose omeprazole, esomeprazole, or pantoprazole are first‑line; they reduce gastric acid output by > 90 % and alleviate ulcer pain.
• H2‑receptor antagonists – famotidine or ranitidine may be added for breakthrough symptoms.
• Somatostatin analogues – octreotide or lanreotide suppress gastrin release, can lessen flushing, and may slow tumor growth.
• Interferon‑α – used in some refractory NETs; can help control hormone secretion.
• Targeted therapy – everolimus (mTOR inhibitor) or sunitinib (tyrosine‑kinase inhibitor) for metastatic disease.
• Chemotherapy – streptozocin‑based regimens are reserved for high‑grade or rapidly progressive tumors.
• Supportive care – oral rehydration solutions, potassium supplementation, and pancreatic enzyme replacement if malabsorption occurs.

Surgical Options

• Enucleation – removal of a small, well‑localized gastrinoma; ideal for solitary lesions.
• Pancreaticoduodenectomy (Whipple procedure) – indicated for larger duodenal tumors or when the tumor involves the pancreatic head.
• Distal pancreatectomy – for tumors in the body or tail of the pancreas.
• Liver metastasectomy or ablation – can improve survival in patients with limited hepatic spread.

Home & Lifestyle Measures

• Maintain a low‑acid diet – avoid caffeine, alcohol, spicy foods, and citrus while you’re stabilizing acid output.
• Eat small, frequent meals to reduce gastrin spikes.
• Stay well‑hydrated; replace electrolytes if diarrhea is persistent.
• Limit triggering substances that may worsen flushing (hot showers, heated environments, nicotine).
• Keep a symptom diary noting timing of flushes, foods, medications, and associated discomfort – this helps the care team adjust therapy.

Prevention Tips

Because ZES is a tumor‑driven condition, true primary prevention is limited. However, you can reduce the frequency and severity of flushing episodes:

• Adhere strictly to prescribed PPI dosing; missed doses often precipitate breakthrough acid and flushing.
• Attend regular follow‑up appointments for imaging and lab monitoring; early detection of tumor growth allows timely intervention.
• Quit smoking and limit alcohol – both increase gastric acid secretion.
• Manage stress through relaxation techniques, as sympathetic activation can worsen flushing.
• Vaccinate against Hepatitis B and maintain hepatitis C screening if you have liver disease; chronic liver injury can amplify neuroendocrine hormone metabolism.
• Discuss any new medications with your gastroenterologist; certain drugs (e.g., niacin, calcium channel blockers) can exacerbate flushing.

Emergency Warning Signs

Summary

Zollinger‑Ellison syndrome flushing is a vivid, often uncomfortable sign that a gastrin‑producing neuroendocrine tumor is hormonally active. While the flushing itself is usually benign, it frequently co‑exists with ulcer disease, severe diarrhea, and systemic effects that demand thorough evaluation.

Early recognition, accurate laboratory and imaging work‑up, and a combined medical‑surgical treatment plan are essential for controlling symptoms, limiting tumor progression, and preserving quality of life. Patients should maintain close communication with their gastroenterology/endocrine team, adhere to high‑dose acid‑suppressive therapy, and immediately seek care for any red‑flag symptoms.

For further reading, see the following reputable sources:

• Mayo Clinic – Zollinger‑Ellison syndrome overview.
• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) – Gastrinomas.
• Cleveland Clinic – Management of neuroendocrine tumors.
• World Health Organization (WHO) – Classification of digestive system tumors.

```